Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder:A randomized, double-blind, placebo-Controlled trial in Canadian women

Journal of Clinical Psychiatry

Volumn 69, Issue 6, 2008, Pages 991-998

  Steiner, Meir ^a   Ravindran, Arun V ^b   Lemelledo, Jean Michel ^c   Carter, Diana ^d   Huang, Jenny O ^e   Anonychuk, Andrea M ^e   Simpson, Scott D ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d British Columbia Women's Reproductive Psychiatric Program   (Canada)

^e GLAXOSMITHKLINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; APPETITE; ARTICLE; BACKACHE; CANADA; CLINICAL TRIAL; COMMON COLD SYMPTOM; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLICULAR PHASE; HEADACHE; HEARTBURN; HUMAN; INSOMNIA; IRRITABILITY; LIBIDO; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PATIENT COMPLIANCE; PREGNANCY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TONSILLITIS; VISUAL ANALOG SCALE; WEIGHT GAIN; XEROSTOMIA; YAWNING;

EID: 46749155577     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0616     Document Type: Article

References (40)

1. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990;147:1634-1636
2. Johnson SR, McChesney C, Bean JA. The epidemiology of premenstrual symptoms in a non-clinical sample: prevalence, natural history and help-seeking behaviour. J Reprod Med 1988;33:340-346
3. Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-132
4. Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women: the Harvard study of moods and cycles. J Affect Disord 2002;70: 125-132
5. Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Womens Ment Health 2003;6:71-77
6. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101-109
7. Steiner M, Pearlstein T, Cohen LS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 2006; 15:57-69
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, Office of Publishing Operations; 1994
9. Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact and burden of premenstrual dysphoric disorder (PMS/ PMDD). Psychoneuroendocrinology 2003;28(suppl 3):1-23
10. Steiner M, Pearlstein TB. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000;61:17-21
11. Rapkin A. A review of treatment of premenstrual syndrome & premenstrual dysphoric disorder. Psychoneuroendocrinology 2003;28:39-53
12. Pcarlstein TB, Bellew KM, Endicott J, et al. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry 2005;7:53-60
13. Cohen LS, Soares CN, Yonkers K A, et al. Paroxetine controlled release tor premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004;66:707-713
14. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-1534
15. Eriksson E, Hedberg MA, Andersch B, et al. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-176
16. Sundblad C, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992;85:39-47
17. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278:983-988
18. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18:390-398
19. Cohen LS, Miner C, Brown E, et al, Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-444
20. Steiner M, Korzekwa M, Lamont J, et al. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997;33:771-774
21. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219-1229
22. Jermain DM, Preece CK, Cykes RL, et al. Late phase seitraline treatment for premenstrual dysphoric disorder: results from a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999;8:328-332
23. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998; 59:76-80
24. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993;9:133-145
25. Landén M, Nissbrandt H, Allgulander C, et al. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007;32:153-161
26. Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled-release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193:352-360
27. Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder, CNS Drags 2004;18:453-468
28. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, Md: US Dept Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976
29. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
30. Steiner M, Streiner DL, Pham B. Validation of a revised visual analogue scale for premenstrual mood symptoms: results from prospective and retrospective trials. Can J Psychiatry 2005;50:179-184
31. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrorne: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980;62:177-190
32. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of premenstrual mood symptoms. Int Clin Psychopharmacol 1996;11:89-95
33. Vickers AJ. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. BMC Med Res Methodol 2005;5:35
34. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 2001;1:6
35. Guidance for Industry: E9 Statistical Principals for Clinical Trials. Rockville, Md: US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research; 1998
36. Bellew KM, Cohen LS, Lambert J, et al. Long-term treatment of PMDD. Presented at the 156th annual meeting of the American Psychiatric Association; May 19, 2003; San Francisco, Calif
37. Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002;24:417-433
38. Ravindran LN, Woods SA, Steiner M, et al. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Arch Womens Ment Health 2007; 10:125-127
39. Eriksson E, Ekman A, Sinclair S, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 2008;28:195-202
40. Sundblad C, Wikander I, Andersch B, et al. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Eur Neuropsychopharmacol 1997;7:201-206